Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects

• Published in: Journal of thoracic oncology Vol. 14; no. 3; pp. 527 - 539
• Main Authors: Guarrera, Simonetta, Viberti, Clara, Cugliari, Giovanni, Allione, Alessandra, Casalone, Elisabetta, Betti, Marta, Ferrante, Daniela, Aspesi, Anna, Casadio, Caterina, Grosso, Federica, Libener, Roberta, Piccolini, Ezio, Mirabelli, Dario, Dianzani, Irma, Magnani, Corrado, Matullo, Giuseppe
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2019; Copyright by the International Association for the Study of Lung Cancer
• Subjects: Aged; Asbestos - adverse effects; Asbestos exposure; Biomarkers, Tumor - blood; Biomarkers, Tumor - genetics; Carcinogens - toxicity; Case-control discrimination; Case-Control Studies; DNA - blood; DNA - chemistry; DNA - genetics; DNA Methylation; Early biomarker; Female; Follow-Up Studies; Humans; Lung Neoplasms - blood; Lung Neoplasms - diagnosis; Lung Neoplasms - etiology; Lung Neoplasms - pathology; Male; Malignant pleural mesothelioma; Mesothelioma - blood; Mesothelioma - diagnosis; Mesothelioma - etiology; Mesothelioma - pathology; Mesothelioma, Malignant; Occupational Exposure - adverse effects; Pleural Neoplasms - blood; Pleural Neoplasms - diagnosis; Pleural Neoplasms - etiology; Pleural Neoplasms - pathology; Prognosis; ROC Curve; Early biomarker; Malignant pleural mesothelioma; DNA-methylation; Case-control discrimination; Asbestos exposure
• ISSN: 1556-0864; 1556-1380; 1556-1380
• DOI: 10.1016/j.jtho.2018.10.163

Malignant pleural mesothelioma (MPM) is an aggressive tumor strongly associated with asbestos exposure. Patients are usually diagnosed when current treatments have limited benefits, highlighting the need for noninvasive early diagnostic tests to monitor asbestos-exposed people. We used a genome-wide...